Home » Newsletters » BioWorld Science

BioWorld Science

April 29, 2010

View Archived Issues

Concert Pharmaceuticals claims new inhibitors of VEGFR-1, -2 and -3

Clinical data disclosed on Locteron/ribavirin vs. PEG-Intron/ribavirin in HCV genotype 1

Synta claims new dual CRAC and IL-2 inhibitors

Actelion claims novel orexin receptor antagonists

U.S. scientists claim new fused diimidazodiazepine agents

Pfizer details discovery and activity of dual PI3K/mTOR inhibitor PF-04691502

Phase II data presented on pasireotide in Cushing's disease and acromegaly

In vivo safety and antitumor activity of ABI-013 disclosed

L-Hyd4FC shows potent in vivo activity in HBV-infected mice

MK-5172 shows potent preclinical activity against resistance-linked HCV NS3/4a protease variants

Enrollment complete in OSI's phase III trial of erlotinib in NSCLC

Vertex provides pipeline update for first quarter of 2010

Erythropoietin does not show benefit in pediatric cardiac surgery

Osiris achieves milestone for remestemcel-L development progress in Japan

Clovis and Ventana to jointly develop diagnostic test for CO-1.01 trial in pancreatic cancer

ChronTech provides update on ChronSeal and ChronVac-C trials

FDA grants orphan drug status to Atir for the reduction of transplant-related mortality

Covidien launches Exalgo extended-release tablets in U.S. for pain management

Dexlansoprazole now available under new name Dexilant in U.S.

Pharmaxis resubmits Adriol NDA to FDA for diagnosis of asthma

Phase II brostallicin/cisplatin trial in triple-negative breast cancer planned

NeuroSearch claims new dopamine and serotonin receptor modulators

AdventRx to resubmit ANX-530 NDA in fourth quarter of 2010

BioCryst reports on phase IIa trial of BCX-4208 in patients with gout

DARA and NCI collaborate to advance KRN-5500 in cancer trial

Diamyd Medical continues phase III trials of Diamyd in diabetes

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 16, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 16, 2025.
Deals and an M&A strengthen end-of-year numbers
BioWorld
Two large deals and an acquisition, totaling about $4.64 billion in all, are helping wrap up what’s turning out to be a strong year. Through the first 11 months...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...
Neutrophils put the brakes on fat loss
BioWorld Science
Fat tissue balances energy by storing lipids during times of abundance and mobilizing them when needed, yet sustained metabolic stress demands mechanisms that...